Payment overview · 2025
General Payments
$752.25
22 reported records · 9 companies
Healthcare provider profile · identity verified
Venu Kumar Luthra, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MELBOURNE, FL · NPI 1932202546
Verified facts
What the public records show
CMS Open Payments records show Venu Kumar Luthra, MD received $752.25 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 65.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $489.23 | 65.0% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.44 | 7.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.43 | 6.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.04 | 5.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.92 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.67 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.53 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.68 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.31 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $752.25 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $489.23 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $93.10 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.44 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 147 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 439 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 93 |
| Gabapentin | Gabapentin | 236 | 55 |
| Losartan Potassium | Losartan Potassium | 232 | 58 |
| Furosemide | Furosemide | 187 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 48 |
| Lisinopril | Lisinopril | 171 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 51 |
| Simvastatin | Simvastatin | 151 | 38 |
| Carvedilol | Carvedilol | 148 | 36 |
| Eliquis | Apixaban | 147 | 26 |
| Potassium Chloride | Potassium Chloride | 146 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 44 |
| Alprazolam | Alprazolam | 120 | 29 |
| Jardiance | Empagliflozin | 118 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 25 |
| Trazodone Hcl | Trazodone Hcl | 117 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 23 |
| Omeprazole | Omeprazole | 109 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 28 |
| Sertraline Hcl | Sertraline Hcl | 104 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 31 |
| Donepezil Hcl | Donepezil Hcl | 100 | 20 |
| Memantine Hcl | Memantine Hcl | 97 | 22 |
| Xarelto | Rivaroxaban | 96 | 22 |
| Metformin Hcl | Metformin Hcl | 85 | 23 |
| Mirtazapine | Mirtazapine | 76 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 24 |
| Bupropion Xl | Bupropion Hcl | 73 | 17 |
| Tramadol Hcl | Tramadol Hcl | 73 | 16 |
| Azithromycin | Azithromycin | 72 | 53 |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Entresto | Sacubitril/Valsartan | 65 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 21 |
| Atenolol | Atenolol | 62 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Lorazepam | Lorazepam | 56 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Allopurinol | Allopurinol | 51 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 14 |
| Methylprednisolone | Methylprednisolone | 50 | 39 |
| Gemtesa | Vibegron | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 15 |
| Prednisone | Prednisone | 48 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 37 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 20 |
| Finasteride | Finasteride | 38 | 13 |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 17 |
| Famotidine | Famotidine | 34 | 15 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 11 |
| Actemra Actpen | Tocilizumab | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 21 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $752.25 · 22 records | Amgen Inc. | CREON, Cologuard Collection Kit, ELIQUIS, GEMTESA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error